<DOC>
	<DOCNO>NCT00651378</DOCNO>
	<brief_summary>This study assess whether add ezetimibe 10 mg/d ongoing treatment atorvastatin 10 mg/d effective switch subject treatment rosuvastatin 10 mg/d double dose atorvastatin 20 mg/d effective achieve goal LDL-cholesterol &lt; 2.5 mmol/L . Treatment phase 6 week .</brief_summary>
	<brief_title>Switching Rosuvastatin Versus Adding Ezetimibe Atorvastatin Versus Doubling Dose Atorvastatin Patients With Hypercholesterolemia Risk Factors ( P03708 )</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>18 year 75 year age ; Stabilized atorvastatin 10 mg daily subject report history take least 80 % daily dose 4 week precede Visit 1 ; LDLC concentration great equal 2.5 mmol/L less equal 160 mg/dL ( less equal 4.1 mmol/L ) base blood specimen take Visit 1 , use Friedewald calculation describe Protocol , Section 8.8 . ( The lipid profile Visit 3 ( baseline ) subsequent visit kept `` blinded '' data analysis ) ; Triglyceride concentration le 350 mg/dL ( le 3.99 mmol/L ) base blood specimen take Visit 1 ; Documented atherosclerotic disease , CHD , diabetes mellitus ; Liver transaminases ( ALT , AST ) less 50 % upper limit normal , active liver disease , CPK le 50 % upper limit normal test blood specimen take Visit 1 ; Clinical laboratory test ( CBC , blood chemistry , urinalysis ) take Visit 1 must within normal limit clinically acceptable Investigator ; Had previously prescribe cholesterol lower diet exercise program least 4 week prior Visit 1 advise continue diet exercise program study ; Reported stable weight history least 4 week prior randomization Visit 3 ( baseline visit ) ; Women receive hormonal therapy , include hormone replacement , estrogen antagonist/agonist , oral contraceptive , must maintain stable dose regimen least 8 week willing continue regimen duration study ; Women childbearing potential ( included woman less 1 year postmenopausal woman become sexually active ) must use acceptable method birth control ( example , hormonal contraceptive , medically prescribe IUD , condom combination spermicide ) surgically sterilize ( example , hysterectomy tubal ligation ) . Free clinically significant disease hyperlipidemia , CHD , diabetes mellitus would interfere study evaluation ; Understood able adhere dose visit schedule , demonstrate willingness participate study comply procedure sign write informed consent . Consumption great 14 alcoholic drink per week . ( A drink : beer [ 1/2 pint 250 ml ] , glass wine , single measure spirit ) ; Any condition situation , opinion Investigator , might pose risk subject interfere participation study ; Body mass index ( BMI ) &gt; = 35 Kg/m^2 Visit 2 ( Screening ) ; Women pregnant nursing ; Failure observe designate washout period prohibit medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>